Stammdaten
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Unternehmen & Branche
| Name | Cadrenal Therapeutics, Inc. |
|---|---|
| Ticker | CVKD |
| CIK | 0001937993 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 13,9 Mio. USD |
| Beta | 1,55 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -13,237,362 | -6.64 | 4,326,708 | 2,738,726 | |
| 2025-09-30 | 10-Q | -2,685,705 | -1.31 | 4,087,622 | 2,734,947 | |
| 2025-06-30 | 10-Q | -3,667,287 | -1.87 | 5,978,431 | 4,298,913 | |
| 2025-03-31 | 10-Q | -3,845,380 | -2.09 | 7,953,262 | 6,113,096 | |
| 2024-12-31 | 10-K | -10,651,368 | -8.73 | 10,123,533 | 7,439,575 | |
| 2024-09-30 | 10-Q | -2,407,829 | -2.18 | 4,679,293 | 3,412,351 | |
| 2024-06-30 | 10-Q | -2,392,982 | -2.24 | 5,457,171 | 3,992,254 | |
| 2024-03-31 | 10-Q | -1,663,288 | -1.56 | 7,048,431 | 6,192,116 | |
| 2023-12-31 | 10-K | -8,357,086 | -9.29 | 8,519,250 | 7,692,375 | |
| 2023-09-30 | 10-Q | -1,036,451 | -1.01 | 9,311,618 | 8,745,820 | |
| 2023-06-30 | 10-Q | -1,003,001 | -0.09 | 3,559,026 | 3,175,922 | |
| 2023-03-31 | 10-Q | -5,173,574 | -0.48 | 4,482,064 | 4,065,262 | |
| 2022-12-31 | 10-K | -6,714,329 | -0.85 | 778,174 | -5,551,150 | |
| 2022-09-30 | 10-Q | -1,026,114 | -0.13 | -1,179,823 | ||
| 2022-06-30 | 10-Q | -502,141 | 0.07 | -670,838 | ||
| 2022-03-31 | 10-Q | -176,648 | -0.02 | -169,147 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.